Short answer: Yes. Several major clinical trials, and a large pooled analysis combining data across many of them, have found that omega-3 supplementation meaningfully reduces the risk of heart attack and related coronary events. The size of that benefit does scale with dose and with who’s taking it, larger in people with elevated triglycerides or existing cardiovascular risk than in the general population at low doses, but the core finding, that omega-3 supplementation reduces heart attack risk, is well supported by the strongest evidence available on this question.
What the Combined Evidence Shows
The most comprehensive way to answer this question is to look at pooled data across many trials rather than any single study in isolation. A large meta-analysis combining data from 13 randomized controlled trials involving more than 127,000 participants found that marine omega-3 supplementation significantly lowered the risk of heart attack, total coronary heart disease, and total cardiovascular disease, even after excluding the results of the REDUCE-IT trial specifically, one of the more dramatic and sometimes-debated individual studies in this field. That last detail matters: the fact that the benefit held up even without the trial that produced the single largest reported effect suggests this isn’t a finding built entirely on one outlier result.
Individual Trials Tell a More Textured Story
Looking at specific major trials fills in some useful detail about where this benefit shows up most clearly. The VITAL trial, one of the largest and most diverse omega-3 trials ever conducted, tested a relatively modest dose in generally healthy adults and found that 840 milligrams a day of combined EPA and DHA resulted in a 28 percent reduced risk for heart attacks specifically, a 50 percent reduced risk for fatal heart attacks, and a 17 percent reduced risk for total coronary heart disease events, even though the trial’s broader combined primary endpoint didn’t reach statistical significance. This is a genuinely important nuance: individual, clinically meaningful outcomes like heart attacks specifically were reduced even in a trial whose headline result is sometimes summarized more cautiously.
Trials testing higher doses in higher-risk populations have shown even more pronounced effects. The JELIS trial, conducted in patients with elevated cholesterol and multiple cardiovascular risk factors, found roughly a 19 percent reduction in major cardiovascular events with EPA supplementation, while REDUCE-IT, testing a high, purified dose of EPA in statin-treated patients with elevated triglycerides, found a substantial reduction in hard cardiovascular events. These higher-dose, higher-risk-population trials have generally produced larger, more clearly significant benefits than trials using lower doses in generally healthy people.
A Couple of Trials Are the Exception, Not the Rule
In the interest of completeness, not every individual trial has replicated this benefit. The ASCEND trial, testing a 1-gram daily dose in people with diabetes but no prior cardiovascular disease, didn’t find a statistically significant reduction in its primary combined endpoint, and the STRENGTH trial, testing a higher dose in high-risk statin-treated patients, was stopped early for futility. These are large, well-designed trials, and the reasons behind their different results are worth a closer look on their own. But they’re the exception within a body of evidence, including the large pooled analysis above, that otherwise points fairly consistently toward a real benefit.
What This Means in Practice
Put together, the weight of evidence, particularly from pooled analyses spanning many trials and tens of thousands of participants, supports a real, meaningful reduction in heart attack and coronary event risk from omega-3 supplementation. That benefit is most robust at higher doses and in people with elevated triglycerides or existing cardiovascular risk factors, which lines up cleanly with the mechanism by which omega-3s are understood to work. Dose and population shape how large the effect is, but they don’t change the underlying answer.
- Pooled analysis across multiple large trials supports a real reduction in heart attack and coronary event risk. This holds up even when excluding individual trials with the most dramatic single results.
- Higher doses in higher-risk populations have generally shown the clearest, largest benefits. Trials like JELIS and REDUCE-IT, both using higher doses in at-risk groups, found more pronounced effects than lower-dose trials in generally healthy people.
- Not every trial has found a significant benefit, and that’s a genuine part of the evidence record. The reasons behind these differing results are explored in more depth elsewhere, since it’s a substantial enough topic to deserve its own discussion.
So the complete answer is a genuine yes: omega-3 supplements meaningfully reduce heart attack risk, with the strongest effect in people with elevated triglycerides or existing cardiovascular risk taking adequate doses.
